Cocaine responsiveness or anhedonia in rats treated with methylphenidate during adolescence

Neurotoxicology and Teratology

Volumn 32, Issue 4, 2010, Pages 432-442

  Ferguson, Sherry A ^a,b   Boctor, Sherin Y ^a,b  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Adolescence; Cocaine; Conditioned place preference; Methylphenidate; Rat; Saccharin

Indexed keywords

COCAINE; METHYLPHENIDATE; SACCHARIN;

ANHEDONIA; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CONDITIONING; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; ESTRADIOL BLOOD LEVEL; ESTRUS CYCLE; FEMALE; HYDROCORTISONE BLOOD LEVEL; LIOTHYRONINE BLOOD LEVEL; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD BEHAVIOR; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL; THYROXINE BLOOD LEVEL;

AGE FACTORS; ANIMALS; BODY WEIGHT; CHOICE BEHAVIOR; COCAINE; CONDITIONING, OPERANT; CORTICOSTERONE; ESTRADIOL; ESTROUS CYCLE; EXPLORATORY BEHAVIOR; FEMALE; FOOD PREFERENCES; HYDROCORTISONE; MALE; METHYLPHENIDATE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS; TESTOSTERONE; THYROXINE; TRIIODOTHYRONINE;

ANIMALIA; RATTUS; RODENTIA;

EID: 77953020830     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ntt.2010.03.007     Document Type: Article

References (61)

1. Achat-Mendes C., Anderson K.L., Itzhak Y. Methylphenidate and MDMA adolescent exposure in mice: long-lasting consequences on cocaine-induced reward and psychomotor stimulation in adulthood. Neuropharmacology 2003, 45:106-115.
2. Adriani W., Leo D., Greco D., Rea M., di Porzio U., Laviola G., Perrone-Capano C. Methylphenidate administration to adolescent rats determines plastic changes on reward-related behavior and striatal gene expression. Neuropsychopharmacology 2006, 31:1946-1956.
3. Andersen S.L., Arvanitogiannis A., Pliakas A.M., LeBlanc C., Carlezon W.A. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat. Neurosci. 2002, 5:13-14.
4. Augustyniak P.N., Kourrich S., Rezazadeh S.M., Stewart J., Arvanitogiannis A. Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder. Behav. Brain Res. 2006, 167:379-382.
5. Balcombe J.P., Barnard N.D., Sandusky C. Laboratory routines cause animal stress. Contemp. Top. Lab. Anim. Sci. 2004, 43:42-51.
6. Bardo M.T., Rowlett J.K., Harris M.J. Conditioned place preference using opiate and stimulant drugs: a meta-analysis. Neurosci. Biobehav. Rev. 1995, 19:39-51.
7. Bereket A., Turan S., Karaman M.G., Haklar G., Ozbay F., Yazgan M.Y. Height, weight, IGF-I, IGFBP-3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment. Horm. Res. 2005, 63:159-164.
8. Bolanos C.A., Barrot M., Berton O., Wallace-Black D., Nestler E.J. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol. Psychiatry 2003, 54:1317-1329.
9. Bolanos C.A., Willey M.D., Maffeo M.L., Powers K.D., Kinka D.W., Grausam K.B., Henderson R.P. Antidepressant treatment can normalize adult behavioral deficits induced by early-life exposure to methylphenidate. Biol. Psychiatry 2008, 63:309-316.
10. Brandon C.L., Marinelli M., Baker L.K., White F.J. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology 2001, 25:651-661.
11. Brown A.P., Dinger N., Levine B.S. Stress produced by gavage administration in the rat. Contemp. Top. Lab. Anim. Sci. 2000, 39:17-21.
12. Carlezon W.A., Mague S.D., Andersen S.L. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol. Psychiatry 2003, 54:1330-1337.
13. Cunningham C.L., Ferree N.K., Howard M.A. Apparatus bias and place conditioning with ethanol in mice. Psychopharmacology (Berl) 2003, 170:409-422.
14. Dafny N., Yang P.B. The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res. Bull. 2006, 68:393-405.
15. Disney E.R., Elkins I.J., McGue M., Iacono W.G. Effects of ADHD, conduct disorder, and gender on substance use and abuse in adolescence. Am. J. Psychiatry 1999, 156:1515-1521.
16. Dobrovolsky V.N., Boctor S.Y., Twaddle N.C., Doerge D.R., Bishop M.E., Manjanatha M.G., Kimoto T., Miura D., Heflich R.H., Ferguson S.A. Flow cytometric detection of Pig-A mutant red blood cels using an erythroid-specific antibody: Application of the method for evaluating the in vivo genotoxicity of methylphenidate in adolescent rats. Environ Mol Mutagen 2010, 51:138-145.
17. Ferguson S.A., Boctor S.Y. Use of food wafers for multiple daily oral treatments in young rats. J. Am. Assoc. Lab. Anim. Sci. 2009, 48:292-295.
18. Ferguson S.A., Cisneros F.J., Gough B.J., Ali S.F. Four weeks of oral isotretinoin treatment causes few signs of general toxicity in male and female Sprague-Dawley rats. Food Chem. Toxicol. 2005, 43:1289-1296.
19. Ferguson S.A., Cisneros F.J., Hanig J.P., Berry K.J. Oral treatment with ACCUTANE((R)) does not increase measures of anhedonia or depression in rats. Neurotoxicol. Teratol. 2007, 29:642-651.
20. Ferguson S.A., Delclos K.B., Newbold R.R., Flynn K.M. Dietary ethinyl estradiol exposure during development causes increased voluntary sodium intake and mild maternal and offspring toxicity in rats. Neurotoxicol. Teratol. 2003, 25:491-501.
21. Gaub M., Carlson C.L. Gender differences in ADHD: a meta-analysis and critical review. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36:1036-1045.
22. Greenhill L.L., Perel J.M., Rudolph G., Feldman B., Curran S., Puig-Antich J., Gardner R. Correlations between motor persistence and plasma levels in methylphenidate-treated boys with ADHD. Int. J. Neuropsychopharmacol. 2001, 4:207-215.
23. Halladay L.R., Iniguez S.D., Furqan F., Previte M.C., Chisum A.M., Crawford C.A. Methylphenidate potentiates morphine-induced antinociception, hyperthermia, and locomotor activity in young adult rats. Pharmacol. Biochem. Behav. 2009, 92:190-196.
24. Hibel L.C., Granger D.A., Cicchetti D., Rogosch F. Salivary biomarker levels and diurnal variation: associations with medications prescribed to control children's problem behavior. Child Dev. 2007, 78:927-937.
25. Joyce P.R., Donald R.A., Nicholls M.G., Livesey J.H., Abbott R.M. Endocrine and behavioral responses to methylphenidate in normal subjects. Biol. Psychiatry 1986, 21:1015-1023.
26. Katusic S.K., Barbaresi W.J., Colligan R.C., Weaver A.L., Leibson C.L., Jacobsen S.J. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J. Child Adolesc. Psychopharmacol. 2005, 15:764-776.
27. Kippin T.E., Fuchs R.A., Mehta R.H., Case J.M., Parker M.P., Bimonte-Nelson H.A., See R.E. Potentiation of cocaine-primed reinstatement of drug seeking in female rats during estrus. Psychopharmacology (Berl) 2005, 182:245-252.
28. Kollins S.H. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr. Med. Res. Opin. 2008, 24:1345-1357.
29. Kuczenski R., Segal D.S. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J. Neurosci. 2002, 22:7264-7271.
30. Kuczenski R., Segal D.S. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol. Psychiatry 2005, 57:1391-1396.
31. Lagace D.C., Yee J.K., Bolanos C.A., Eisch A.J. Juvenile administration of methylphenidate attenuates adult hippocampal neurogenesis. Biol. Psychiatry 2006, 60:1121-1130.
32. Laviola G., Macri S., Morley-Fletcher S., Adriani W. Risk-taking behavior in adolescent mice: psychobiological determinants and early epigenetic influence. Neurosci. Biobehav. Rev. 2003, 27:19-31.
33. Mague S.D., Andersen S.L., Carlezon W.A. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol. Psychiatry 2005, 57:120-125.
34. Mannuzza S., Klein R.G., Truong N.L., Moulton J.L., Roizen E.R., Howell K.H., Castellanos F.X. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am. J. Psychiatry 2008, 165:604-609.
35. Martin-Iverson M.T., Reimer A.R., Sharma S. Unbiased cocaine conditioned place preferences (CPP) obscures conditioned locomotion, and nimodipine blockade of cocaine CPP is due to conditioned place aversions. Psychopharmacology (Berl) 1997, 130:327-333.
36. McCabe S.E., Teter C.J., Boyd C.J. Medical use, illicit use and diversion of prescription stimulant medication. J. Psychoactive Drugs 2006, 38:43-56.
37. McGough J.J., McBurnett K., Bukstein O., Wilens T.E., Greenhill L., Lerner M., Stein M. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2006, 16:351-356.
38. Mott T.F., Leach L., Johnson L. Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?. J. Fam. Pract. 2004, 53:659-661.
39. National Research Council Guide for the Care and Use of Laboratory Animals 1996, National Academy Press, Washington DC. Editoin Edition.
40. Quinn D., Bode T., Reiz J.L., Donnelly G.A., Darke A.C. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. J. Clin. Pharmacol. 2007, 47:760-766.
41. Quinones-Jenab V., Ho A., Schlussman S.D., Franck J., Kreek M.J. Estrous cycle differences in cocaine-induced stereotypic and locomotor behaviors in Fischer rats. Behav. Brain Res. 1999, 101:15-20.
42. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Brain Res. Rev. 1993, 18:247-291.
43. Russo S.J., Festa E.D., Fabian S.J., Gazi F.M., Kraish M., Jenab S., Quinones-Jenab V. Gonadal hormones differentially modulate cocaine-induced conditioned place preference in male and female rats. Neuroscience 2003, 120:523-533.
44. Russo S.J., Jenab S., Fabian S.J., Festa E.D., Kemen L.M., Quinones-Jenab V. Sex differences in the conditioned rewarding effects of cocaine. Brain Res. 2003, 970:214-220.
45. Sell S.L., Scalzitti J.M., Thomas M.L., Cunningham K.A. Influence of ovarian hormones and estrous cycle on the behavioral response to cocaine in female rats. J. Pharmacol. Exp. Ther. 2000, 293:879-886.
46. Spencer T.J., Wilens T.E., Biederman J., Weisler R.H., Read S.C., Pratt R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 2006, 28:266-279.
47. Steinhoff K.W. Special issues in the diagnosis and treatment of ADHD in adolescents. Postgrad. Med. 2008, 120:60-68.
48. Thanos P.K., Michaelides M., Benveniste H., Wang G.J., Volkow N.D. Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacol. Biochem. Behav. 2007, 87:426-433.
49. Torres-Reveron A., Dow-Edwards D.L. Repeated administration of methylphenidate in young, adolescent, and mature rats affects the response to cocaine later in adulthood. Psychopharmacology (Berl) 2005, 181:38-47.
50. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict. Biol. 2007, 12:227-462.
51. Valvassori S.S., Frey B.N., Martins M.R., Reus G.Z., Schimidtz F., Inacio C.G., Kapczinski F., Quevedo J. Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats. Behav. Pharmacol. 2007, 18:205-212.
52. Vezina P. Sensitization, drug addiction and psychopathology in animals and humans. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1553-1555.
53. Volkow N.D., Insel T.R. What are the long-term effects of methylphenidate treatment?. Biol. Psychiatry 2003, 54:1307-1309.
54. Volkow N.D., Swanson J.M. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am. J. Psychiatry 2003, 160:1909-1918.
55. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley J.S., Dewey S., Ashby C., Liebermann J., Hitzemann R., et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry 1995, 52:456-463.
56. Weizman R., Dick J., Gil-Ad I., Weitz R., Tyano S., Laron Z. Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity. Life Sci. 1987, 40:2247-2252.
57. Wilens T.E., McBurnett K., Bukstein O., McGough J., Greenhill L., Lerner M., Stein M.A., Conners C.K., Duby J., Newcorn J. and others, Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch. Pediatr. Adolesc. Med. 2006, 160:82-90.
58. Wiley M.D., Poveromo L.B., Antapasis J., Herrera C.M., Bolanos Guzman C.A. kappa-Opioid system regulates the long-lasting behavioral adaptations induced by early-life exposure to methylphenidate. Neuropsychopharmacology 2009, 34:1339-1350.
59. Winsberg B.G., Kupietz S.S., Sverg J., Hungund B.L., Young N.L. Methylphenidate oral dose plasma concentrations and behavioral response in children. Psychopharmacology (Berl) 1982, 76:329-332.
60. Wizemann T.M., Pardue M.-L. Exploring the Biological Contributions to Human Health: Does Sex Matter? 2001, National Academies Press, Washington, D.C. Editoin Edition.
61. Zakharova E., Leoni G., Kichko I., Izenwasser S. Differential effects of methamphetamine and cocaine on conditioned place preference and locomotor activity in adult and adolescent male rats. Behav. Brain Res. 2009, 198:45-50.